-
Mashup Score: 4
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 4
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Possible Treatment Identified for Rare Kidney Cancer Subtype - 5 day(s) ago
Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Possible Treatment Identified for Rare Kidney Cancer Subtype - 7 day(s) ago
Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 17What Are Biomarkers and How Are They Used in Kidney Cancer? - 11 day(s) ago
An expert said that he is optimistic about the future use of biomarkers in the kidney cancer space.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 8
Charles Ryan interviews Ignacio Peláez to discuss the evolving landscape of second-line treatments for kidney cancer, emphasizing the dependency of these treatments on first-line therapy choices. Dr. Peláez explains that the selection of second-line treatments is influenced by the initial therapy, which has undergone a therapeutic revolution from TKI monotherapy to combinations of immunotherapy…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
How rapid innovation in frontline #KidneyCancer treatment regimens creates uncertainty in determining optimal second-line therapies. @nacho_pelaez and @charlesryanmd @PCFnews discuss the evolving landscape of second-line treatments for kidney cancers > https://t.co/0f670Mh9Qi https://t.co/6fR8h9CO22
-
-
Mashup Score: 2Bispecific Antibody Inhibiting PD-1 and CTLA-4 Demonstrates Effectiveness Against Advanced Kidney Cancer in Early Study - Martin Voss - 23 day(s) ago
Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC. Dr. Voss provides an overview of volrustomig, highlighting its unique ability to inhibit PD-1 and selectively bind CTLA-4 on cells co-expressing both receptors, aiming for targeted action in the tumor microenvironment. He reviews the dose-finding study’s…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Bispecific antibody inhibiting PD-1 and CTLA-4 demonstrates effectiveness against advanced #KidneyCancer in early study. @MVossMD @MSKCancerCenter joins @PBarataMD @caseccc to discuss volrustomig, the effects, abilities, and ongoing trials in this space > https://t.co/6yMV0JMRaN https://t.co/KykU06o6MC
-
-
Mashup Score: 20Advances in the management of renal cell carcinoma - 29 day(s) ago
KEY POINTS Renal cell carcinoma (RCC) is the 10th most common cancer in Canada, with an estimated 8100 new cases and 1950 deaths from the disease annually.[1][1] Renal cell carcinoma accounts for more than 90% of kidney malignancies. Its incidence increases with age, with a global median age at
Source: www.cmaj.caCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20Advances in the management of renal cell carcinoma - 1 month(s) ago
KEY POINTS Renal cell carcinoma (RCC) is the 10th most common cancer in Canada, with an estimated 8100 new cases and 1950 deaths from the disease annually.[1][1] Renal cell carcinoma accounts for more than 90% of kidney malignancies. Its incidence increases with age, with a global median age at
Source: www.cmaj.caCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19Advances in the management of renal cell carcinoma - 1 month(s) ago
KEY POINTS Renal cell carcinoma (RCC) is the 10th most common cancer in Canada, with an estimated 8100 new cases and 1950 deaths from the disease annually.[1][1] Renal cell carcinoma accounts for more than 90% of kidney malignancies. Its incidence increases with age, with a global median age at
Source: www.cmaj.caCategories: General Medicine News, Partners & KOLsTweet
“More or less, [SC Opdivo] can achieve the same goals as intravenously administered [Opdivo],” said lead investigator Dr. Saby George of @roswellpark, regarding #KidneyCancer. Read more: https://t.co/Fzo7HwGihr